London, UK: 02 August 2006…. deltaDOT Ltd, a developer of highly innovative enabling technologies and products for bioscience research, has announced the expansion of its senior team with appointment of Dr Andrew Carr as Chairman of the Board with immediate effect. 

Dr Andrew Carr has over 20 years of experience of commercialising life sciences innovation. Previously, Andrew was a Director of Amersham Plc, a FTSE 100 company, and CEO of Amersham Biosciences, where he was responsible for a $1 billion turnover. Andrew has a PhD in Zoology from the University of Nottingham. He has been Executive Chairman and is now Non Executive Chairman of Akubio Ltd. 

Commenting on the new appointments, Dr Tony Baxter, CEO of DeltaDOT said: “We are delighted to announce the appointment of Andrew as Chairman. Andrew’s extensive sector specific experience is ideally suited for this key position and his timely addition to the company will significantly strengthen the Board.”  

Dr Andrew Carr commented: “I am delighted to be joining the team at such an exciting time. deltaDOT’s technology represents a major step forward in biomolecular separations and I look forward to contributing to the ongoing commercial success of the company.“ 

- ENDS -

Notes to editors:

About deltaDOT Ltd

http://www.deltadot.com 

deltaDOT is a biotechnology company that is developing and commercialising highly innovative enabling technologies and products in the bioscience arena.

The company was founded in 2000 and is a spin out from the Imperial College of Science, Technology and Medicine in London, UK. It is focused on the harnessing of cutting-edge particle physics technology and its application to the needs of biomolecular separation, including proteins, DNA and RNA analysis. The company has a strong proprietary position and extensive expertise in instrumentation, microfluidics, automation, computing and analysis which will contribute to improvements in knowledge, profitability and process time throughout drug discovery and general life sciences research.

About Label Free Intrinsic Imaging^TM (LFII^TM)

deltaDOT’s core technology, Label Free Intrinsic Imaging (LFII^TM), coupled with proprietary powerful analyses, forms the basis of its product offering. LFII^TM allows the direct monitoring of unlabelled biomolecules in real time, resulting in much faster, more accurate results at a fraction of the cost of conventional approaches. deltaDOT’s first product was a High Performance Capillary Electrophoresis instrument; other products being developed are a high throughput protein folding device and systems capable of rapid, unbiased analysis of genomic, proteomic and chemical content of unknown substances and threats

For more information please contact: 

At deltaDOT:

Dr Tony Baxter, CEO

Bessemer Building (RSM) Level 1

Prince Consort Road

South Kensington

London SW7 2BW
http://www.deltadot.com 

Tel: +44 (0)20 7594 1001

Fax: +44 (0)20 7594 1006

Email: a.baxter@deltadot.com 

Media relations:

At Northbank Communications

Lorna Watson, Senior Account Manager

Northbank Communications Ltd
The Media Village, 131-151 Great Titchfield Street,
London, W1W 5BB, UK 

Tel: +44 (0)20 7886 8157
Fax: +44 (0)20 7886 8151

Email: l.watson@northbankcommunications.com